Philip Morris International Inc.: 10-K Risk Factor Changes

2024 vs 2023  ·  SEC EDGAR  ·  2026-05-22
Other years: 2026 vs 2025 · 2025 vs 2024
⚠ AI-Generated

The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.

Philip Morris International added five new risks in 2024, with the most substantive additions addressing credit market disruptions, product recalls, asset impairment write-downs, production facility disruptions, and illicit tobacco products - while removing its pandemic risk disclosure from 2023. The 11 modified risks reflect heightened focus on geopolitical instability and natural disasters (consolidated into its international operations risk), inflationary pressures on costs and demand, and product innovation constraints, suggesting the company views macroeconomic and supply chain vulnerabilities as increasingly material concerns. The retention of 17 unchanged risks indicates stability in PMI's core risk profile around regulatory, litigation, and tax matters, even as the company recalibrated disclosure to emphasize emerging operational and financial market challenges.

✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

5
New Risks
1
Removed
11
Modified
17
Unchanged
🟢 New in Current Filing Disruptions in the credit markets or changes to our credit ratings may adversely affect our business. 🔒
🟢 New in Current Filing We could decide, or be required to, recall products, which could have a material adverse effect on our business, reputation, results of operations, cash flows or financial position. 🔒
🟢 New in Current Filing We may be required to write down assets due to impairment, which could have a material adverse effect on our results of operations or financial position. 🔒
🟢 New in Current Filing A prolonged disruption of our production facilities could have a material adverse effect on our business, financial condition and results of operations. 🔒
🟢 New in Current Filing We lose revenues as a result of counterfeiting, contraband, cross-border purchases, "illicit whites," non-tax-paid volume produced by local manufacturers, and counterfeiting of our smoke-free products' devices and consumables. 🔒
🔴 No Match in Current Filing Our business, results of operations, cash flows and financial position may be materially adversely impacted by an epidemic, endemic or pandemic, such as COVID-19. 🔒
🟡 Modified Because we have operations in numerous countries, our results may be adversely impacted by economic, regulatory and political developments, natural disasters, pandemics or conflicts. 🔒
🟡 Modified A sustained period of elevated inflation across the markets in which we operate could result in higher operating and financing costs and lead to reduced demand for our products. 🔒
🟡 Modified Our ability to grow profitability may be limited by our inability to introduce new products, enter new markets, maintain sufficient production capacity, or improve our margins through higher pricing and improvements in our brand and geographic mix. 🔒
🟡 Modified We may be unable to anticipate changes in adult consumer preferences. 🔒
🟡 Modified The effects of climate change, other environmental issues, and related legal or regulatory responses may have a negative impact on our business and results of operations. 🔒
🟡 Modified Swedish Match and Vectura Fertin Pharma may have liabilities that are not known to us. 🔒
🟡 Modified Our reported results could be adversely affected by unfavorable currency exchange rates and currency fluctuations could impair our competitiveness. Our results could also be adversely affected by capital controls or by foreign currency exchange constraints or devaluations. 🔒
🟡 Modified Accounting adjustments related to the Acquisitions could adversely affect our financial results. 🔒
🟡 Modified We may be unsuccessful in our attempts to introduce, commercialize, and grow reduced-risk products in existing and new markets, and regulators may prohibit or significantly restrict the commercialization of these products or the communication of scientifically substantiated information and claims. 🔒
🟡 Modified We are significantly dependent on our and third-party information technology networks and systems, and a cybersecurity incident or attack against those networks or systems may adversely impact our business and operations. 🔒
🟡 Modified We may be unable to fully realize the expected benefits from the acquisitions of Swedish Match or Vectura Fertin Pharma. 🔒
17 changes in this historical filing

Historical year-over-year comparisons (2024 vs 2023 and earlier) are available on the Pro plan.

Get full access — from $29/month Already a Pro subscriber? View full diff →